Last reviewed · How we verify
Epidural local anesthetic injection
Epidural local anesthetic injection, developed by the University of Washington, is a marketed product used for pain management. The key composition patent expires in 2028, providing a period of exclusivity that supports current market position. The primary risk is the potential increase in competition once the patent expires.
At a glance
| Generic name | Epidural local anesthetic injection |
|---|---|
| Also known as | lidocaine |
| Sponsor | University of Washington |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- From Battlefield to Recovery: Continuous Regional Anaesthesia for War-Related Lower Limb Trauma
- Ultrasound-Guided Transversus Abdominis Plane Block Versus Epidural Block for Umbilical Hernia Analgesia
- Erector Spinae Plane vs Caudal Epidural Steroid in Lumbar Spinal Stenosis Resistant to Conservative Therapy (NA)
- Efficacy of Sphenopalatine Block Compared to Blood Patch in the Management of Post-dural Puncture Headaches (PHASE3)
- Local Anesthetics in Cervical Epidural Injection
- The Effect of Adding a Local Anesthetic to Transforaminal Epidural Injection in Cervical Disc Herniation. (NA)
- EXORA Block vs Epidural Analgesia in Gynecological Surgery (NA)
- Effect of Epidural Needle Injection on Catheter Placement Success During Painless Labour (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epidural local anesthetic injection CI brief — competitive landscape report
- Epidural local anesthetic injection updates RSS · CI watch RSS
- University of Washington portfolio CI